Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients
Author:
Affiliation:
1. Department of Gynecology; Weifang Yidu Central Hospital; Weifang China
2. Department of Gynecology; Weifang People's Hospital; Weifang China
Funder
Shandong Province
Publisher
Wiley
Subject
Obstetrics and Gynaecology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jog.13710/fullpdf
Reference43 articles.
1. Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period 1978-2002;Hannibal;Acta Obstet Gynecol Scand,2008
2. Statistics on cancer in China: Cancer registration in 2002;Yang;Eur J Cancer Prev,2005
3. Cancer statistics: Updated cancer burden in China;Chen;Chin J Cancer Res,2015
4. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2012;Jung;Cancer Res Treat,2015
5. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Related Clinical Factors of Platinum-Based Chemotherapy Resistance in Patients with Epithelial Ovarian Cancer;Gynecologic and Obstetric Investigation;2024-06-05
2. Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience;Turkish Journal of Oncology;2023
3. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery;Cochrane Database of Systematic Reviews;2022-09-26
4. Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review;Current Oncology Reports;2022-08-15
5. Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer;Chemotherapy;2021-11-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3